Amgen traded at $246.73 this Tuesday July 5th, increasing $1.18 or 0.48 percent since the previous trading session. Looking back, over the last four weeks, Amgen gained 0.53 percent. Over the last 12 months, its price rose by 1.26 percent. Looking ahead, we forecast Amgen to be priced at 238.90 by the end of this quarter and at 219.99 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
246.73
Daily Change
0.48%
Yearly
1.26%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,838.00 26.00 0.68% 3.79%
AbbVie 153.93 0.13 0.08% 33.01%
Agios Pharmaceuticals 25.45 2.09 8.95% -55.55%
ALKERMES 31.43 0.90 2.95% 22.97%
Amgen 246.73 1.18 0.48% 1.26%
Astrazeneca 65.51 -0.44 -0.67% 9.37%
Biogen 212.58 1.95 0.93% -38.36%
Bluebird Bio 5.05 0.77 17.99% -83.73%
BioMarin Pharmaceutical 86.36 1.38 1.62% 2.12%
Bristol-Myers Squibb 75.96 -0.88 -1.15% 13.97%
Coherus Biosciences 8.54 0.71 9.07% -37.34%
Exelixis 22.27 0.70 3.25% 21.10%
Genmab 2,407.00 54.00 2.29% -8.41%
Gilead Sciences 62.34 -0.02 -0.03% -8.87%
GlaxoSmithKline 1,786.60 -16.00 -0.89% 24.57%
Glaxosmithkline 43.30 -0.45 -1.03% 8.09%
Intercept Pharmaceuticals 15.15 1.02 7.22% -20.43%
Incyte Corp 79.25 1.58 2.03% -4.91%
Ionis Pharmaceuticals 37.86 -0.20 -0.53% -3.74%
J&J 178.14 -1.38 -0.77% 6.05%
Eli Lilly 327.18 2.47 0.76% 38.98%
Merck & Co 92.64 0.22 0.24% 18.60%
Moderna Inc 155.54 5.59 3.73% -33.34%
Mirati Therapeutics 71.96 0.78 1.10% -56.07%
Neurocrine Biosciences 98.30 -0.95 -0.96% 0.87%
Novartis 80.91 -0.74 -0.91% -4.31%
Novartis 84.28 -0.08 -0.09% -7.97%
Puma Biotechnology 2.66 -0.12 -4.32% -69.43%
Pfizer 51.64 -0.67 -1.28% 31.43%
PTC Therapeutics 43.78 1.93 4.61% 0.99%
Ultragenyx Pharmaceutical 63.80 1.15 1.84% -30.21%
Regeneron Pharmaceuticals 596.56 1.16 0.19% 2.46%
Roche Holding 319.00 -3.60 -1.12% -9.76%
Sanofi 97.12 -1.22 -1.24% 11.93%
Seattle Genetics 176.77 -3.34 -1.85% 15.91%
Sarepta Therapeutics 75.74 0.03 0.04% 3.43%
Teva Pharmaceutical Industries Ltd 2,746.00 0 0% -13.97%
Vertex Pharmaceuticals 288.98 1.66 0.58% 44.45%

Indexes Price Day Year
US500 3833 6.06 0.16% -11.74%
USND 11322 194.39 1.75% -22.79%
USNDX 11808 222.33 1.92% -20.15%
US30 30950 -26.98 -0.09% -10.49%

Amgen
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.